These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33046271)

  • 41. The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses.
    Boorjian SA; Crispen PL; Lohse CM; Leibovich BC; Blute ML
    Eur Urol; 2008 Oct; 54(4):855-63. PubMed ID: 18487007
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
    Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
    Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
    Halefoglu AM; Ozagari AA
    Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinicopathologic features of clear cell papillary renal cell carcinoma].
    Rao Q; Shen Q; Shi S; Xia Q; Lu Z; Yu B; Zhang R; He Y; Wang X; Ma H; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2014 Nov; 43(11):728-31. PubMed ID: 25582249
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.
    DiNatale RG; Gorelick AN; Makarov V; Blum KA; Silagy AW; Freeman B; Chowell D; Marcon J; Mano R; Sanchez A; Attalla K; Weng S; Voss M; Motzer RJ; Russo P; Coleman JA; Reuter VE; Chen YB; Chan TA; Reznik E; Tickoo SK; Hakimi AA
    Eur Urol Focus; 2021 Mar; 7(2):381-389. PubMed ID: 31813809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
    Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
    BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
    Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
    Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.
    Verbiest A; Couchy G; Job S; Caruana L; Lerut E; Oyen R; de Reyniès A; Tosco L; Joniau S; Van Poppel H; Van Raemdonck D; Van Den Eynde K; Wozniak A; Zucman-Rossi J; Beuselinck B
    Eur Urol; 2018 Oct; 74(4):474-480. PubMed ID: 29463434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-Term Outcomes of Patients With Low Grade Cystic Renal Epithelial Neoplasms.
    Westerman ME; Cheville JC; Lohse CM; Sharma V; Boorjian SA; Leibovich BC; Thompson RH
    Urology; 2019 Nov; 133():145-150. PubMed ID: 31356826
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome.
    Massari F; Ciccarese C; Hes O; Michal M; Caliò A; Fiorentino M; Giunchi F; D'Amuri A; Sanguedolce F; Sabbatini R; Guida A; Ardizzoni A; Porta C; Iacovelli R; Tortora G; Cima L; Ortega C; Lapini A; Martignoni G; Brunelli M
    Pathol Oncol Res; 2018 Jul; 24(3):447-456. PubMed ID: 28695322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.
    Casuscelli J; Becerra MF; Manley BJ; Zabor EC; Reznik E; Redzematovic A; Arcila ME; Tennenbaum DM; Ghanaat M; Kashan M; Stief CG; Carlo M; Voss MH; Feldman DR; Motzer RJ; Chen Y; Reuter VE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
    Eur Urol Focus; 2019 Jul; 5(4):642-649. PubMed ID: 28951115
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intra- and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity.
    Sanfrancesco JM; Eble JN; Grignon DJ; Wang M; Zhang S; Sundaram CP; Idrees MT; Pili R; Kouba E; Cheng L
    Mol Carcinog; 2017 Nov; 56(11):2527-2537. PubMed ID: 28667776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
    Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
    Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression.
    Marcon J; DiNatale RG; Sanchez A; Kotecha RR; Gupta S; Kuo F; Makarov V; Sandhu A; Mano R; Silagy AW; Blum KA; Nassau DE; Benfante NE; Ortiz MV; Carlo MI; Chan TA; Motzer RJ; Voss MH; Coleman J; Russo P; Reuter V; Hakimi AA; Reznik E
    Clin Cancer Res; 2020 Jul; 26(14):3629-3640. PubMed ID: 32220885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Papillary Renal Cell Carcinoma With Microcystic Architecture Is Strongly Associated With Extrarenal Invasion and Metastatic Disease.
    Chan E; Stohr BA; Butler RS; Cox RM; Myles JL; Nguyen JK; Przybycin CG; Reynolds JP; Williamson SR; McKenney JK
    Am J Surg Pathol; 2022 Mar; 46(3):392-403. PubMed ID: 34881751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
    Brooks SA; Brannon AR; Parker JS; Fisher JC; Sen O; Kattan MW; Hakimi AA; Hsieh JJ; Choueiri TK; Tamboli P; Maranchie JK; Hinds P; Miller CR; Nielsen ME; Rathmell WK
    Eur Urol; 2014 Jul; 66(1):77-84. PubMed ID: 24613583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis.
    Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; St-Hilaire PA; Tian Z; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    World J Urol; 2021 Feb; 39(2):461-472. PubMed ID: 32253579
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
    Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE
    Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
    Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
    Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic Underpinnings of Renal Cell Carcinoma With Leiomyomatous Stroma.
    Parilla M; Alikhan M; Al-Kawaaz M; Patil S; Kadri S; Ritterhouse LL; Segal J; Fitzpatrick C; Antic T
    Am J Surg Pathol; 2019 Aug; 43(8):1135-1144. PubMed ID: 30986793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.